By 1943, sales of Zyklon B accounted for 65 percent of Degesch's sales revenue and 70 percent of its gross profits.
Cara 1943 as vendas de Zyklon B compoñían o 65% dos ingresos por vendas de Degesch e o 70% dos seus beneficios brutos.